CN117897175A - 拓扑异构酶i抑制剂的肽缀合物的给药方案 - Google Patents

拓扑异构酶i抑制剂的肽缀合物的给药方案 Download PDF

Info

Publication number
CN117897175A
CN117897175A CN202280044027.3A CN202280044027A CN117897175A CN 117897175 A CN117897175 A CN 117897175A CN 202280044027 A CN202280044027 A CN 202280044027A CN 117897175 A CN117897175 A CN 117897175A
Authority
CN
China
Prior art keywords
compound
pharmaceutically acceptable
administered
acceptable salt
measured
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280044027.3A
Other languages
English (en)
Chinese (zh)
Inventor
V·帕拉尔卡
A·P·德克丽斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
American Business Sbreksa Ii Co
Original Assignee
American Business Sbreksa Ii Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Business Sbreksa Ii Co filed Critical American Business Sbreksa Ii Co
Publication of CN117897175A publication Critical patent/CN117897175A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202280044027.3A 2021-04-29 2022-04-28 拓扑异构酶i抑制剂的肽缀合物的给药方案 Pending CN117897175A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163181640P 2021-04-29 2021-04-29
US63/181,640 2021-04-29
PCT/US2022/071967 WO2022232808A1 (en) 2021-04-29 2022-04-28 Dosing regimens of peptide conjugates of topoisomerase i inhibitors

Publications (1)

Publication Number Publication Date
CN117897175A true CN117897175A (zh) 2024-04-16

Family

ID=81749580

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280044027.3A Pending CN117897175A (zh) 2021-04-29 2022-04-28 拓扑异构酶i抑制剂的肽缀合物的给药方案

Country Status (12)

Country Link
US (1) US20240226308A1 (cg-RX-API-DMAC7.html)
EP (1) EP4329817A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024516825A (cg-RX-API-DMAC7.html)
KR (1) KR20240019097A (cg-RX-API-DMAC7.html)
CN (1) CN117897175A (cg-RX-API-DMAC7.html)
AU (1) AU2022267389A1 (cg-RX-API-DMAC7.html)
CA (1) CA3218253A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023003187A1 (cg-RX-API-DMAC7.html)
IL (1) IL308052A (cg-RX-API-DMAC7.html)
MX (1) MX2023012779A (cg-RX-API-DMAC7.html)
TW (1) TW202308696A (cg-RX-API-DMAC7.html)
WO (1) WO2022232808A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022000449A (es) 2019-07-10 2022-04-25 Cybrexa 2 Inc Conjugados peptídicos de citotoxinas como terapéuticos.
BR112022000297A2 (pt) 2019-07-10 2022-03-15 Cybrexa 3 Inc Conjugados de peptídeos de agentes de alvo de microtúbulos como terapêuticos
WO2025186213A1 (en) 2024-03-04 2025-09-12 Debiopharm International S.A. Combination of a wee1 inhibitor and a topoisomerase 1 inhibitor

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006078816A2 (en) 2005-01-18 2006-07-27 The Board Of Governors For Higher Education Selective delivery of molecules into cells or marking of cells in diseased tissue regions using environmentally senstive transmembrane peptide
CA3032186C (en) 2010-07-13 2022-04-26 Council on Postsecondary Education, State of Rhode Island and Providence Plantations Environmentally sensitive composition comprising a ph triggered peptide and uses thereof
SG10201913073YA (en) * 2015-08-20 2020-03-30 Ipsen Biopharm Ltd Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment
AU2019205325A1 (en) 2018-01-05 2020-08-13 Cybrexa 1, Inc. Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
MX2022000449A (es) 2019-07-10 2022-04-25 Cybrexa 2 Inc Conjugados peptídicos de citotoxinas como terapéuticos.
US20210106648A1 (en) * 2019-10-11 2021-04-15 TOBEBIO Novel Drug Laboratory Co., Ltd. Synergistic combination of chemotherapy and peptide for treating cancer

Also Published As

Publication number Publication date
KR20240019097A (ko) 2024-02-14
CA3218253A1 (en) 2022-11-03
IL308052A (en) 2023-12-01
AU2022267389A9 (en) 2023-11-16
AU2022267389A1 (en) 2023-11-09
EP4329817A1 (en) 2024-03-06
US20240226308A1 (en) 2024-07-11
MX2023012779A (es) 2024-01-16
WO2022232808A1 (en) 2022-11-03
JP2024516825A (ja) 2024-04-17
CL2023003187A1 (es) 2024-05-03
TW202308696A (zh) 2023-03-01

Similar Documents

Publication Publication Date Title
US20110052581A1 (en) Use of picoplatin and cetuximab to treat colorectal cancer
KR20240019097A (ko) 토포이소머라아제 i 억제제의 펩타이드 접합체 투여 요법
KR20150038297A (ko) 아플리베르셉트 또는 지브-아플리베르셉트를 포함하는 제조 물품
JP6425653B2 (ja) 抗腫瘍剤及び抗腫瘍効果増強剤
CA3018145C (en) TREATMENT METHOD FOR TRIPLE-NEGATIVE BREAST CANCER
AU2013402794A1 (en) Cancer treatment with combination of plinabulin and taxane
CN112587666A (zh) 用于治疗癌症的pd-1/pd-l1相互作用的小分子抑制剂和抗pd-1抗体的组合
WO2020187152A1 (zh) 治疗小细胞肺癌的联用药物组合物
KR20180021060A (ko) 항-her2 항체-약물 접합체 및 bcl-2 억제제를 사용한 병용 요법
WO2020233602A1 (zh) 用于联合治疗小细胞肺癌的喹啉衍生物
JP2023065427A (ja) 白金耐性癌の治療
TW202128224A (zh) 抗pd-1抗體和組蛋白去乙醯化酶抑制劑的藥物組合及其用途、使用方法
JP6782932B2 (ja) Npr−aアゴニストの新規用途
JP6359198B1 (ja) がん細胞の代謝の特異性に基づく新規抗悪性腫瘍剤
CN107614015A (zh) 治疗her2阳性局部晚期或先前未治疗的转移性乳腺癌的方法
CN116134155A (zh) 通过施用pd-1抑制剂治疗癌症的方法
AU2018234141A1 (en) Combination between trifluridine/tipiracil hydrochloride, an anti-tumor platinum complex, and an immune checkpoint modulator
CN114667159B (zh) 喹啉衍生物与pd-1单抗的药物组合
WO2026077321A1 (zh) 抗her2抗体药物偶联物和免疫检查点抑制剂的药物组合
WO2023111810A1 (en) Combination therapies and uses for treating cancer
WO2023242105A9 (en) Novel ras inhibitors
CN120605325A (zh) 靶向her2的抗原结合构建体与小分子药物联合治疗乳腺癌的用途
WO2023242102A1 (en) Novel ras inhibitors
HK1249444A1 (en) Methods of treating her2-positive locally advanced or previously untreated metastatic breast cancer
HK1155089A (en) Use of picoplatin and bevacizumab to treat colorectal cancer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination